NeOnc Prices $15M Registered Direct Offering at $4.20 to Redeem Punitive Preferred Stock
NTHI sits 24% above its 52-week low of $3.005 on light trading volume (0.1× avg).
Summary
NeOnc priced a $15 million registered direct offering at $4.20 per share to redeem its Series A preferred stock and fund operations, with warrants adding up to 4.53 million shares of potential future dilution.
Key Events · Financing and Capital Events · NTHI
-
$15M Registered Direct Offering Priced
2,610,715 shares plus 960,715 pre-funded warrants and 3,571,430 five-year warrants at $4.20 per share, raising approximately $13.9 million net of fees.
-
Proceeds Redeem Punitive Preferred Stock
Net proceeds will fund general corporate purposes and redeem the Series A Convertible Preferred Stock, removing the $5 million punitive financing obligation disclosed in the Q2 10-Q.
-
Warrant Overhang of 4.53M Shares
3,571,430 warrants exercisable at $4.20 for five years plus 960,715 pre-funded warrants at $0.0001 create potential future dilution of up to 4.53 million shares.
-
Placement Agent Fees and Lock-Ups
Roth Capital Partners and A.G.P./Alliance Global Partners receive a 7.0% cash fee ($1.05 million) plus $75,000 expense reimbursement; CEO and CMO are locked up for 90 days.
Analysis · NTHI · Life Sciences
NeOnc is raising $15 million at $4.20 per share — a premium to today's $3.715 price — with proceeds earmarked to redeem the Series A Convertible Preferred Stock that carried a punitive $5 million financing obligation disclosed in the Q2 10-Q. The deal adds 2.61 million shares plus 4.53 million warrant-covered shares, creating meaningful overhang, but the capital removes a toxic financing structure and extends runway ahead of pivotal Phase 2a data. Placement agents take 7% in cash fees plus $75,000 in expenses, and the CEO and CMO are locked up for 90 days.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.5% of the 1962 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTHI was trading at $3.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4M. The 52-week trading range was $3.01 to $12.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.